ADC Therapeutics (ADCT) Cash from Investing Activities (2020 - 2026)
ADC Therapeutics (ADCT) posted Cash from Investing Activities of -$32000.0 for Q1 2026, down 104.86% sequentially from $659000.0 in Q4 2025, and up 87.88% YoY from -$17032.3 in Q1 2025.
ADC Therapeutics (ADCT) Cash from Investing Activities (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at -$32000.0 in Q1 2026.
- Quarterly Cash from Investing Activities rose 87.88% year-over-year to -$32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $627000.0 (up 204.5% YoY) and the FY2025 annual result came in at $395000.0, up 145.56% from the prior year.
- Cash from Investing Activities retreated to -$32000.0 in Q1 2026 per ADCT's latest filing, from $659000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $1.7 million in Q4 2022 and troughed at -$1.4 million in Q1 2022.
- A 5-year average of -$293800.0 and a median of -$264000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities slumped 160.24% in 2023, then surged 832.22% in 2025.
- Over 5 years, Cash from Investing Activities stood at $1.7 million in 2022, then tumbled by 119.19% to -$327000.0 in 2023, then surged by 72.48% to -$90000.0 in 2024, then soared by 832.22% to $659000.0 in 2025, then slumped by 104.86% to -$32000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$32000.0, $659000.0, and -$264000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,000.00 |
| Mar 31, 2026 | -32,000.00 |
| Dec 31, 2025 | 659,000.00 |
| Dec 31, 2025 | 659,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Sep 30, 2024 | -216,000.00 |
| Sep 30, 2024 | -216,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Mar 31, 2024 | -531,000.00 |
| Mar 31, 2024 | -531,000.00 |
| Dec 31, 2023 | -327,000.00 |
| Dec 31, 2023 | -327,000.00 |
| Sep 30, 2023 | -661,000.00 |
| Sep 30, 2023 | -661,000.00 |
| Jun 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -1.21 Mn |